SciELO - Scientific Electronic Library Online

 
vol.28 número3La vasectomía: estudio de 300 intervenciones. Revisión de la literatura nacional y de sus complicacionesMutaciones del gen del receptor de andrógenos en pacientes con adenocarcinoma de próstata clínicamente localizado índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Actas Urológicas Españolas

versão impressa ISSN 0210-4806

Resumo

LABORDA RODRIGUEZ, A. et al. Histopathological validation of tissue-microarray technology in urotelial cancer: Our experience. Actas Urol Esp [online]. 2004, vol.28, n.3, pp.215-220. ISSN 0210-4806.

INTRODUCTION: The array technology offers: a big advance to clinic and basic investigator, it provides a variety of technics (immunohystochemistry, FISH, proteomics) to undestand the molecular mechanisms of cancer. It offers scale economy in reagents versus the conventional methods. Array most be ratified because the sample is so reduced. MATERIAL AND METHODS: 52 consecutive cases have been cloosen from paraffin blocks of bladder and ureteral cancer which are 5-7 years old, a tissue array has been made; disks have been arranged in lines and columns, in an aleatory way, in order to guide it’s reading. It has been evaluated by a pathologist with any relation to specimen selection. RESULTS: 87 sheets ha been obtained. Number 1 has been dyed with HE. Has been discrepancy in 27% of sample’s stage. Has not been a discrepancy in hystopathologic diagnostic. There is no sample’s representation in 11 points (17%). DISCUSSION: Our results offer good results in sample’s validation. The sample’s antigenicity of tissue is conserved. Array sample’s represent a 97%, similary to all unit of conventional sections of the specimen.

Palavras-chave : Microarray; Bladder cancer; Renal pelvis cancer; FISH; Immunohistochemistry.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons